A 48-year-old woman with type 2 diabetes mellitus and chronic kidney disease (eGFR 35 mL/min/1.73m²) has inadequate glycemic control on metformin monotherapy (HbA1c 8.5%). Metformin dose has been reduced due to declining renal function. Which agent is the drug of choice to add as second-line therapy in this patient?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.